. 2020 Nov 2;63(23):14151–14183. doi: 10.1021/acs.jmedchem.0c00766

Table 4. Clinical Trials Involving Loss of CDK12 Function.

trial identifier	drug	phase	summary	status and accession date
NCT01434316	Veliparib (PARPi) and 49	I	Studying the safety profile of veliparib and 49 in participants with advanced solid tumors.	Recruiting
NCT01434316	Veliparib (PARPi) and 49	I		September 14, 2011
NCT04272645	Abemaciclib and atezolizumab (both PD-L1 immunotheraputics)	II	Studying the effectivity and safety of abemaciclib and atezolizumab in participants with metastatic castration-resistant prostate cancer with and without “CDK12 loss” mutation.	Withdrawn (coordinating site change)
NCT04272645	Abemaciclib and atezolizumab (both PD-L1 immunotheraputics)	II		February 17, 2020
NCT03570619	Nivolumab and ipilimumab (both PD-L1 immunotheraptics)	II	Studying the efficacy of nivolumab/ipilimumab in combination and nivolumab as a monotherapy in participants with castration-resistant metastatic prostate carcinoma or other solid tumor histologies, with CDK12 loss of function.	Recruiting
NCT03570619	Nivolumab and ipilimumab (both PD-L1 immunotheraptics)	II		June 27, 2018
NCT04104893	Pembrolizumab (PD-L1 immunotheraptic)	II	A study to assess the activity and efficacy of pembrolizumab in participants with progressive metastatic castration-resistant prostate cancer, characterized by a mismatch repair deficiency or biallelic CDK12 inactivation.	Recruiting
NCT04104893	Pembrolizumab (PD-L1 immunotheraptic)	II		September 26, 2019